The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Bispecific antibodies in the treatment pipeline for myeloma in the UK
Salam Youssef, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the use of bispecific antibodies in the treatment of multiple myeloma (MM) in the UK. Available through compassionate access since October 2022, teclistamab and elranatamab are pending NICE approval. Patient selection is based on treatment tolerance, and sequencing depends on prior BCMA-targeted therapy exposure. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Menarini stemline, Janssen; Conference attendance/ travel expenses: Gilead, Beigene, Pfizer.
